Home/Pipeline/Next-Generation Cologuard®

Next-Generation Cologuard®

Colorectal Cancer Screening

DevelopmentActive

Key Facts

Indication

Colorectal Cancer Screening

Phase

Development

Status

Active

Company

Exact Sciences

About Exact Sciences

Exact Sciences is a $20+ billion market cap leader in cancer diagnostics, driven by a mission to prevent, detect earlier, and guide treatment for cancer. Its success is anchored by the dominant Cologuard® colorectal cancer screening test and the globally recognized Oncotype DX® genomic test suite. The company's strategy focuses on expanding its integrated oncology portfolio, notably through the launch of its multi-cancer early detection test, CancerGuard™, and leveraging strategic partnerships like the one with Abbott for enhanced global scale. This positions Exact Sciences to address the full cancer care continuum from screening to treatment guidance.

View full company profile

Therapeutic Areas

Oncology

Other Colorectal Cancer Screening Drugs

Drug	Company	Phase	Status
Urine cfDNA Test for Colon Cancer Screening	JBS Science	Development	Active
iFOB	Pangea Laboratory	Commercial	Active
ColoHealth	New Day Diagnostics	Approved	Active
Occult Blood Testing	EKF Diagnostics	Commercial	Active
CRC Screening Program	Polymedco	Commercial	Active
SimpleScreen CRC	Freenome	Commercial (as LDT)	Active
ColoScape™ / QuantiDNA™	DiaCarta	Commercial	Active
ColonView® Market Penetration	Biohit	Commercial	Active
ColoSense	Geneoscopy	Approved	Active
At-Home Colorectal Cancer Screening	SNT Biotech	Commercial	Active
FIT System & Assay Development	Sentinel Diagnostics	Commercial	Active
Shield	Guardant Health	Pre-Market / Pivotal Studies	Active